Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Healthcare Shares
Down 20% in a year, is the Cochlear share price a bargain buy?
Blue Chip Shares
Experts rate these ASX 200 blue chip shares as buys
Healthcare Shares
Goldman Sachs names 3 ASX healthcare shares to buy
Blue Chip Shares
Analysts name 2 high quality ASX blue chip shares to buy right now
Broker Notes
3 ASX shares to buy in troubled times: expert panel
Dividend Investing
Think Cochlear shares are boring? That might change when you see what $10,000 invested 10 years ago is worth now
Broker Notes
Down 8% in a week, is the Cochlear share price in the buy zone?
Growth Shares
Analysts say these top ASX growth shares are buys
Healthcare Shares
Broker says the Cochlear share price is in the buy zone following Oticon acquisition
Broker Notes
Top brokers name 3 ASX shares to buy today
Healthcare Shares
2 medical tech ASX shares Morgans loves right now
Healthcare Shares
Cochlear share price falls on 'loss making' Oticon Medical acquisition
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
